Faricimab in Neovascular AMD Complicated by Pigment Epithelium Detachment: An AI-Assisted Evaluation of Early Morphological Changes.
Daniele VerittiValentina SaraoMarco GonfiantiniLeopoldo RubinatoPaolo LanzettaPublished in: Ophthalmology and therapy (2024)
Faricimab demonstrates early and significant efficacy in improving PED architecture in patients with nAMD. The rapid morphological improvements observed in this study suggest faricimab may represent a valid therapeutic option for PEDs associated with nAMD.